SCHEMBL913592

SCHEMBL913592

NC(=O)c1cnc(Nc2cccc(NC(=O)N3CCOCC3)c2)nc1NCc1cccc(F)c1

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 14/20 0.74
NTRK1 P04629 4/20 0.64
JAK2 O60674 1/20 0.60
JAK1 P23458 1/20 0.60
JAK3 P52333 1/20 0.60
AURKA O14965 1/20 0.58
RPS6KB1 P23443 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913798 0.93 STAT6 (0.65) STAT6NTRK1JAK2JAK1JAK3
SCHEMBL915060 0.92 STAT6 (0.70) STAT6NTRK1AURKARPS6KB1
SCHEMBL912281 0.91 NTRK1 (0.64) STAT6NTRK1JAK2JAK1JAK3
SCHEMBL914786 0.85 AURKA (0.55) STAT6NTRK1JAK2JAK1JAK3
SCHEMBL913657 0.84 STAT6 (0.65) STAT6NTRK1AURKARPS6KB1
SCHEMBL913548 0.84 STAT6 (0.67) STAT6NTRK1AURKARPS6KB1
SCHEMBL914215 0.84 JAK3 (0.68) STAT6NTRK1JAK2JAK1JAK3
SCHEMBL914035 0.83 STAT6 (0.68) STAT6NTRK1AURKARPS6KB1
SCHEMBL912929 0.83 STAT6 (0.65) STAT6NTRK1JAK2JAK1JAK3
SCHEMBL913205 0.83 STAT6 (0.61) STAT6NTRK1JAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US claimed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US claimed
US-8853230-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-07 US disclosed
US-8853230-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-07 US disclosed
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US disclosed
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US disclosed
US-8367689-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367689-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US disclosed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US disclosed
WO-2010129802-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137673-A1 INHIBITORS OF JAK JAK1, JAK2, JAK3 STAT6 16/4885NTRK1 3318/4885JAK2 2/4885
US-20110005947-A1 INHIBITORS OF JAK JAK1, JAK2, JAK3 STAT6 16/4885NTRK1 3318/4885JAK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.